# Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects

> **NCT01888393** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 23 (actual)

## Conditions studied

- Hepatic Impairment
- Healthy

## Interventions

- **DRUG:** lumacaftor 200 mg q12h + ivacaftor 250 mg q12h

## Key facts

- **NCT ID:** NCT01888393
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2013-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01888393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01888393, "Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01888393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*